Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer-Reference-Cited by-同舟云学术

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

Published:2016-03-28 Issue:8 Volume:76 Page:2301-2313
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Herrera-Abreu Maria Teresa,Palafox Marta,Asghar Uzma,Rivas Martín A.,Cutts Rosalind J.,Garcia-Murillas Isaac,Pearson Alex,Guzman Marta,Rodriguez Olga,Grueso Judit,Bellet Meritxell,Cortés Javier,Elliott Richard,Pancholi Sunil,Lord Christopher J.,Baselga José,Dowsett Mitch,Martin Lesley-Ann,Turner Nicholas C.,Serra Violeta

Funder

Cancer Research UK

Catalan Agency AGAUR

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors;Redox Biology;2024-10

2. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer;Journal of Clinical Oncology;2024-09-05

3. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

4. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

5. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23